In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Benefits of the remote monitoring of cardiac implanted electronic devices in the clinical practice of a high-volume hospital center.

Session Poster session 2

Speaker Francisco Mendez Zurita

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Home and Remote Patient Monitoring
  • Session type : Poster Session
  • FP Number : P1177

Authors : F Mendez Zurita (Barcelona,ES), E Rodriguez Font (Barcelona,ES), C Alonso Martin (Barcelona,ES), J Guerra Ramos (Barcelona,ES), B Campos Garcia (Barcelona,ES), O Alcalde Rodriguez (Barcelona,ES), H Espinosa Viamonte (Barcelona,ES), A El Amrani Rani (Barcelona,ES), J Maldonado Chavez (Barcelona,ES), X Vinolas Prat (Barcelona,ES)

F Mendez Zurita1 , E Rodriguez Font1 , C Alonso Martin1 , J Guerra Ramos1 , B Campos Garcia1 , O Alcalde Rodriguez1 , H Espinosa Viamonte1 , A El Amrani Rani1 , J Maldonado Chavez1 , X Vinolas Prat1 , 1Hospital de la Santa Creu i Sant Pau - Barcelona - Spain ,



Remote monitoring (RM) of cardiac implanted electronic devices (CIED) is a technology established in the clinical practice, and should be offered as part of the usual care of patients. The RM accessibility, benefits and safety have been demonstrated in randomized clinical trials. However, data in daily clinical practice with unselected patients and including all manufacturers is limited.

The purpose of this study was to assess the impact of RM in the clinical practice. A detailed review of RM experience was performed in a tertiary referral hospital.


All patients with an CIED and RM followed-up in our center in 2017 were included. All manufacturers were included. Clinical and demographic characteristics were analyzed. The digital device data obtained in remote and in hospital follow-up visits were transferred in a system software package. Patients with ICD were seen annually with in clinic device interrogation, patients with CRT were seen every six months. All patients were scheduled for a RM transmission every four months. The total number of scheduled and unscheduled in hospital visits was analyzed. The amount of remote visits that represented clinically significant conditions was evaluated. A protocol of classification by colors is used in our center: green (non clinical relevance), yellow (mild clinical - electrical instability), red (critical clinical - electrical instability, ERI).


A total of 860 patients are in RM (64% ICD, 30% CRT-D, 6% CRT-P, 78.2% males, 65 ± 12.93 years, 65.96%  primary prevention). The number of in hospital follow-up was 1.69 visits /patient /year. A total of 2968 transmissions were received and analyzed during the study period (3.45 transmissions /patient / year). Of this total 273 (9.2%) transmissions were unscheduled (alert, event, duplicate or unintentional). A 21.44% of RM transmissions were classified as yellow or red, according our local protocol. A 4.94% of the transmissions induced an unscheduled in hospital visit to reprogramming or initiation / uptritaion medication, of which 10 cases were due to asymptomatic new onset atrial fibrillation.


RM allows a reduction in hospital follow-up visits, generates a very low proportion of unscheduled visits, and allows early detection of asymptomatic events.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are